ப்ராஸ்டேட் புற்றுநோய் வேலை குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Astellas and Pfizer s XTANDI® Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study

Astellas and Pfizer s XTANDI® Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesAndrew armstrongAmerican society of clinical oncologyEuropean commissionLab abnormalitiesExchange commissionProstate cancer working groupAstellas pharma incPfizer incEuropean unionEuropean society for medical oncologyMedivation incDuke cancer institute centerAstellas pharmaEuropean society

Unexpected Race-Based Findings in Novel Prostate Cancer Study

email article Black men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) plus prednisone had similar survival outcomes but more toxicity compared with white men, a multicenter prospective study showed. Median radiographic progression-free survival (PFS), the study s primary outcome, was similar between the two groups, at 16.6 and 16.8 months for the Black and white patients, respectively, reported Daniel George, MD, of Duke University Medical Center in Durham, North Carolina, and colleagues. And median overall survival was nearly identical (35.9 vs 35.7 months, respectively). In addition, Black men had a median time to prostate-specific antigen (PSA) progression (TTP) of 16.6 months compared with 11.5 months for white men, as shown in the team s study in

United statesNorth carolinaDuke university medical centerMike bassettDaniel georgeProstate cancer working groupBlack americansஒன்றுபட்டது மாநிலங்களில்வடக்கு கரோலினாடியூக் பல்கலைக்கழகம் மருத்துவ மையம்மைக் பாசெட்டேனியல் ஜார்ஜ்ப்ராஸ்டேட் புற்றுநோய் வேலை குழுகருப்பு அமெரிக்கர்கள்

Astellas XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer

Share this article Share this article TOKYO, May 4, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) announced today that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). Men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years, 1 underscoring the need for new treatment options. With this indication, enzalutamide is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC.

United statesKenji yasukawaAndrew armstrongAmerican society of clinical oncologyEuropean commissionProstate cancer working groupAstellas pharma incEuropean medicines agencyPrnewswire astellas pharma incMedivation incDuke cancer institute centerCancer biologyDuke cancer instituteUrologic cancersHormone sensitive prostate cancerSafety information

Astellas XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesKenji yasukawaAndrew armstrongAmerican society of clinical oncologyEuropean commissionProstate cancer working groupAstellas pharma incEuropean medicines agencyPrnewswire astellas pharma incMedivation incDuke cancer institute centerCancer biologyDuke cancer instituteUrologic cancersHormone sensitive prostate cancerSafety information

Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesKenji yasukawaAndrew krivoshikAstellas pressEuropean medicines authorityOncology developmentEuropean commissionDrug administrationProstate cancer working groupAstellas pharma incEuropean medicines agencyPrnewswire astellas pharma incDevices agencyCommittee for medicinal products human useMedivation incMedicinal products